Physician profile
Christopher Nicholas Cecchini
NPI 1013907997
$6,583.08
in general payments reported to CMS, 2019-2025
22 companies · $608 in 2025
The $608 reported for 2025 was more than what 82% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,344 · 2020: $597 · 2021: $536 · 2022: $1,718 · 2023: $973 · 2024: $807 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,387.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,154.99 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $800.98 | 2022-2025 | Infuse, Miebo, Xiidra |
| Abbvie INC. | $783.38 | 2022-2025 | Vuity |
| Shire North American Group INC | $774.82 | 2019 | |
| Sun Pharmaceutical Industries INC. | $530.13 | 2019-2025 | Cequa |
| Coopervision INC. | $525.33 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $510.70 | 2019-2021 | |
| Allergan, INC. | $455.13 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $368.22 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $294.39 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Biotissue Holdings INC. | $85.01 | 2022-2024 | |
| Genentech USA, INC. | $45.95 | 2019 | |
| Kala Pharmaceuticals, INC. | $45.14 | 2021 | |
| Amgen INC. | $42.24 | 2024 | Tepezza |
| Dompe US, INC. | $33.98 | 2024 | Oxervate |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $25.51 | 2019 | |
| New World Medical,INC. | $22.25 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $20.32 | 2024 | Catalys System |
| Horizon Therapeutics Plc | $19.34 | 2023 | Tepezza |
| Johnson & Johnson Vision Care, INC. | $18.86 | 2024 | |
| Alcon Vision LLC | $14.74 | 2022 | |
| Aerie Pharmaceuticals, INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Cecchini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.